IHS Holding (IHS) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago. These figures ...

Yalla Group Limited on Tuesday announced its financial results for the second quarter (Q2) of the fiscal year 2025, reporting ...

Bitfarms Ltd. (BITF) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.07 per share a year ago. These figures are ...

TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Voya Target Solution Trusts’ primary performance objective is to outperform its strategic allocation composite benchmark over ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C.

Investing.com -- Micronics Japan reported second-quarter probe card sales of ¥18.5 billion for the fiscal year ending December 2025, up from ¥13.7 billion in the first quarter. Operating profit rose ...

Quest Resource (QRHC) delivered earnings and revenue surprises of -200.00% and -17.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

APS segment revenue was $507 million, adjusted EBITDA $80 million, and backlog at $1.57 billion, down 10% year-over-year. MTS segment pro forma revenue was $92 million, with adjusted EBITDA of $18 ...

SINGAPORE] Private-sector economists and the Ministry of Trade and Industry (MTI) warned that the second half of 2025 will ...

In his August 11 Q2 2025 update, Ventum Capital Markets analyst Rob Goff maintained a “Buy” rating on Illumin Holdings ...